Mobile

A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment vers...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005163-94

A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment versus 300 mg Aspirin® N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate superiority of 500 mg and 250 mg Aspirin® i.v. (BAY 81-8781) treatment over oral treatment with 300 mg Aspirin® N tablets to inhibit thromboxane A2-release (measured as stable metabolite thromboxane B2 in serum, TXB2) at 5 minutes after single dose of study drug administration. Thromboxane release is a surrogate parameter for the inhibition of platelet aggregation and thrombus formation in vivo

Critère d'inclusion

  • Acute coronary syndrome (ACS)

Liens